2-26-2

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 15120

Total Pages in this Submission

TO THE ASSISTANT COMMISSIONER FOR PATENTS

B x Patent Application

Washington, D.C. 20231	
and 37 C.F.R. 1.53(b) is a new the for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new the filling under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new the filling under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new the filling under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new the filling under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new the filling under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new the filling under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new the filling under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new the filling under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new the filling under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new the filling under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new the filling under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new the filling under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new the filling under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new the filling under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new the filling under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new the filling under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new the filling under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new the filling under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new the filling under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new the filling under 35 U.S.C. 111(a) and 37	utility patent application for an
invention entitled:	
COMPOUNDS THAT AFFECT CD83 EXPRESSION, PHARMACEUTICAL COMPO	OSITIONS COMPRISING
SAID COMPOUNDS AND METHODS FOR IDENTIFYING SAID COMPOUNDS	
	2 💻
and invented by:	
Joachim Hauber	23.8
Alexander Thorsten Prechtel	12 02
	\$C 1
If a CONTINUATION APPLICATION, check appropriate box and supply the requisite	information:
Continuation Divisional Continuation-in-part (CIP) of prior app	lication No.:
Which is a:	
Continuation 🔲 Divisional 🔲 Continuation-in-part (CIP) of prior app	lication No.:
到 Which is a: ,	
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior app	lication No :
O Continuation & Divisional & Continuation in part (on) or prior app	
Enclosed are: Application Elements	
1. 🛛 Filing fee as calculated and transmitted as described below	
2. Specification having pages and including the form	ollowing:
a. 🛛 Descriptive Title of the Invention	
, in the second	
b. Cross References to Related Applications (if applicable)	
c. Statement Regarding Federally-sponsored Research/Development (if	applicable)
d. Reference to Microfiche Appendix (if applicable)	
1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1	
e. 🗵 Background of the Invention	
e. 🛭 Background of the Invention	
 e. Background of the Invention f. Brief Summary of the Invention g. Brief Description of the Drawings (if drawings filed) 	
e. 🛭 Background of the Invention f. 🖾 Brief Summary of the Invention	

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 15120

Total Pages in this Submission

3.	×	Dra	wing(s) (when nec	essary as prescribed by 3	5 USC 113)	
	a.	×	Formal	Number of Sheets	15	
	b.		Informal	Number of Sheets		
4.		Oat	h or Declaration			
	a.		Newly executed (original or copy)	Unexecuted	
	b.		Copy from a prior	application (37 CFR 1.63	(d)) (for continuation/	divisional application only)
	c.		With Power of Att	orney 🔲 Without P	ower of Attorney	
	d.			IVENTOR(S) attached deleting invento 3(d)(2) and 1.33(b).	r(s) named in the pr	ior application,
5.		The Box	entire disclosure d	as being part of the d	n which a copy of the	ne oath or declaration is supplied under companying application and is hereby
6.		Cor	nputer Program in	Microfiche (Appendix)		
7.	×	Nuc	cleotide and/or Ami	no Acid Sequence Submi	sion (if applicable, a	all must be included)
	a.	X	Paper Copy			
	b.	X	Computer Readal	ole Copy (identical to com	outer copy)	
	C.	X	Statement Verifying	ng Identical Paper and Co	mputer Readable C	ору
				Accompanying A	pplication Parts	
8.		Ass	ignment Papers (c	over sheet & document(s))	
9.		37 (CFR 3.73(B) Stater	nent <i>(when there is an as</i>	signee)	
10.		Eng	lish Translation Do	cument (if applicable)		
11.		Info	rmation Disclosure	Statement/PTO-1449	☐ Copies of IDS	Citations
12.	X	Pre	liminary Amendme	nt		
13.	×	Ack	nowledgment post	card		
14.	×	Cer	tificate of Mailing			
			First Class	Express Mail (Specify La	bel No.): EV05276	6852US

Application El m nts (Continued)

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 15120

Total Pages in this Submission

Acc mpanying Application Parts (Continued) 16. Additional Enclosures (please identify below): Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2) Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application. Warning An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 15120

Total Pages in this Submission

Fee Calculation and Transmittal

CLAIMS AS FILED For #Filed #Allowed Rate #Extra Fee \$576.00 **Total Claims** 52 - 20 = 32 \$18.00 Indep. Claims 3 0 \$0.00 - 3 = \$84.00 x \$280.00 Multiple Dependent Claims (check if applicable) **BASIC FEE** \$740.00 \$0.00 OTHER FEE (specify purpose) **TOTAL FILING FEE** \$1,596.00 A check in the amount of \$1,596.00 to cover the filing fee is enclosed. ☑ The Commissioner is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below. A duplicate copy of this sheet is enclosed. Charge the amount of as filing fee. ☑ Credit any overpayment. ☐ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.37. ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowand pursuant to 37 C.F.R. 1.311(b). Leopold Presser Registration No.: 19,827 Dated: December 19, 2001 SCULLY, SCOTT, MURPHY & PRESSER 400 Garden City Plaza Garden City, New York 11530

(516)742-4343

cc:

oplicant(s): Joachim Hau	AILING BY "EXPRESS Malber, et al.	MAIL" (37 CFR 1.10)	Docket No. 15120
Serial No. Unassigned	Filing Date Herewith	Examiner Unassigned	Group Art Uni Unassigned
vention: COMPOUNDS COMPRISING	SAID COMPOUNDS AND ME	ESSION, PHARMACEUTICAL OF THOOS FOR IDENTIFYING S	AID COMPOUNDS
I hereby certify that the fo	ellowing correspondence:		
is being denosited with th		f correspondence) se "Express Mail Post Office to I	Addressee" service und
		·	
		nt Commissioner for Patents, Wa	ashington, D.C. 20231 c
December 19, (Date)	2001		
		Janet Grossm	an
		Janet Grossm (Typed or Printed Name of Person Mai	
		(Typed or Printed Name of Person Mai	lling Correspondence)
		(Typed or Printed Name of Person Mailing Co	lling Correspondence) orrespondence)
		(Typed or Printed Name of Person Mail (Signature of Person Mailing Co	lling Correspondence) orrespondence) US
		(Typed or Printed Name of Person Mailing Co	lling Correspondence) orrespondence) US
		(Typed or Printed Name of Person Mail (Signature of Person Mailing Co	lling Correspondence) orrespondence) US
		(Typed or Printed Name of Person Mail (Signature of Person Mailing Co	lling Correspondence) orrespondence) US
	Note: Each paper must hav	(Typed or Printed Name of Person Mail (Signature of Person Mailing Co	lling Correspondence) orrespondence) US
	Note: Each paper must hav	(Typed or Printed Name of Person Mail (Signature of Person Mailing Co EV052766852) ("Express Mail" Mailing Lab	lling Correspondence) orrespondence) US
	Note: Each paper must hav	(Typed or Printed Name of Person Mail (Signature of Person Mailing Co EV052766852) ("Express Mail" Mailing Lab	lling Correspondence) orrespondence) US
	Note: Each paper must hav	(Typed or Printed Name of Person Mail (Signature of Person Mailing Co EV052766852) ("Express Mail" Mailing Lab	lling Correspondence) orrespondence) US
	Note: Each paper must hav	(Typed or Printed Name of Person Mail (Signature of Person Mailing Co EV052766852) ("Express Mail" Mailing Lab	lling Correspondence) orrespondence) US
	Note: Each paper must hav	(Typed or Printed Name of Person Mail (Signature of Person Mailing Co EV052766852) ("Express Mail" Mailing Lab	lling Correspondence) orrespondence) US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Joachim Hauber, et al.

Examiner: Unassigned

Serial No.: Unassigned

Art Unit: Unassigned

Filing Date: Herewith

Docket: 15120

For:

COMPOUNDS THAT AFFECT CD83

EXPRESSION, PHARMACEUTICAL COMPOSITIONS COMPRISING SAID Date: December 19, 2001

COMPOUNDS AND METHODS FOR **IDENTIFYING SAID COMPOUNDS**

Assistant Commissioner for Patents Washington, DC 20231

CLAIM OF PRIORITY

Sir:

Applicant in the above-identified application hereby claims the right of priority in connection with Title 35 U.S.C. §1.19 and in support thereof, will submit a certified copy of British Patent Application Number 0031145.6 filed December 20, 2000, in due course.

Registration No. 19.8

Scully, Scott, Murphy & Presser 400 Garden City Plaza Garden City, NY 11530 (516) 742-4343

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" mailing label number: EV052766852US

Date of Deposit: December 19, 2001

I hereby certify that this New Patent Application and Fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, DC 20231.

Dated: December 19, 2001

Agnet Grossman